维拉帕米与心脏：药理学及治疗学考量

Verapamil and the heart: Pharmacological and Therapeutic Considerations.

作者信息

DPhil B N

出版信息

N Z Med J. 1975 Nov 26;82(552):339-43.

Abstract

Verapamil is a new anti-anginal and anti-arrhythmic drug whose pharmacological actions can be related to its specific blocking effect on the transmembrane transport of calcium ions. Intravenous verapamil slows the ventricular rate in atrial fibrillation and flutter with an occasional patient reverting to sinus rhythm. The drug promptly terminates most cases of paroxysmal supraventricular tachycardias. It is likely to become the initial agent of choice in the acute treatment of this arrhythmia. Verapamil is not effective in ventricular tachycardia or in atrial fibrillation complicating the WPW syndrome. Few side effects are encountered following intravenous verapamil expecially when the drug is given slowly. Verapamil is also effective in angina in a dose of 120mg tds orally. Little is known of the metabolism and pharmacokinetic of verapamil but the available experience in arrhythmias clearly justifies further study.

摘要

维拉帕米是一种新型抗心绞痛和抗心律失常药物，其药理作用可能与其对钙离子跨膜转运的特异性阻断作用有关。静脉注射维拉帕米可减慢心房颤动和心房扑动时的心室率，偶尔有患者恢复窦性心律。该药能迅速终止大多数阵发性室上性心动过速病例。它很可能成为这种心律失常急性治疗的首选初始药物。维拉帕米对室性心动过速或伴有预激综合征的心房颤动无效。静脉注射维拉帕米后很少出现副作用，尤其是缓慢给药时。维拉帕米口服剂量为120mg，每日三次时对心绞痛也有效。关于维拉帕米的代谢和药代动力学知之甚少，但在心律失常方面的现有经验显然证明有必要进一步研究。